Digestive Enzymes
Also sold as: Pancreatic enzyme replacement · Pancrelipase · Lactase · Bromelain · Papain
Enzymes that break down food components, ranging from targeted lactase to prescription pancreatic replacement. Evidence depends on the enzyme and diagnosis; broad OTC blends are not interchangeable with prescribed PERT.
Energy
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Energy: No established general energy benefit from OTC blends in adequately nourished healthy adults; evidence for treating diagnosed pancreatic insufficiency is a separate outcome.
REALITY CHECK // The strongest evidence is for prescription PERT in diagnosed pancreatic insufficiency, not a universal anti-bloat capsule. Lactase is a targeted option for lactose intolerance. Gluten-degrading supplements have not established protection that would allow a person with celiac disease to eat gluten safely.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No nutritional EFSA or US upper limit is supplied for enzymes. High-dose prescription pancrelipase is constrained by clinical risk, including fibrosing colonopathy; the dossier flags doses above 10,000 lipase units/kg/day particularly in children with cystic fibrosis. This is a medical safety threshold, not an OTC mg allowance.
Summary
Prescription pancreatic enzyme replacement improves fat digestion in diagnosed exocrine pancreatic insufficiency (EPI). Targeted lactase has small-trial support for lactose intolerance. Broad OTC blends lack convincing evidence for general bloating in healthy people; a 16-person lipase study only assessed acute fullness after a fatty meal.
Mechanism
Lipase, amylase and protease act in the intestinal lumen on fat, starch and protein. Lactase breaks lactose down before colonic fermentation. Enteric protection preserves pancreatic enzymes against gastric acid; bromelain and papain have different clinical and safety questions.
Typical studied dose
Enzyme activity, not mg, determines dosing. The dossier describes prescription PERT around 25,000–40,000 lipase units per main meal, approximately half with snacks, individualized by the treating clinician. Lactase is expressed in FCC units and bromelain in GDU/FIP activity. No valid mg conversion or generic blend target can be supplied.
Upper limit
No nutritional EFSA or US upper limit is supplied for enzymes. High-dose prescription pancrelipase is constrained by clinical risk, including fibrosing colonopathy; the dossier flags doses above 10,000 lipase units/kg/day particularly in children with cystic fibrosis. This is a medical safety threshold, not an OTC mg allowance.
Popular stacks with Digestive Enzymes
Not enough stack data yet. A combination with Digestive Enzymes appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Prescription enteric-coated pancrelipase / pancreatin Best for: Diagnosed EPI under medical supervision. |
Unstandardized: active content unknown | no comparable trial range | Acts locally; enteric-coated microspheres protect enzymes from acid. Generally tolerated; excessive doses can cause fibrosing colonopathy. |
Studied standard [FORM // CHECK_SPECIFICATION] Unavailable in this mg calculator: compare lipase activity units and the actual prescription. |
| Targeted lactase / tilactase Best for: Lactase deficiency / lactose-containing meals. |
Unstandardized: active content unknown | no comparable trial range | Acts locally on lactose in the digestive tract. Generally well tolerated in the small studies. |
Good option [FORM // CHECK_SPECIFICATION] FCC activity and lactose load matter; no mg equivalence or 100% activity assumption. |
| Bromelain proteolytic enzyme Best for: Assessing specific proteolytic-enzyme evidence. |
Unstandardized: active content unknown | no comparable trial range | Activity specification matters; mg does not establish proteolytic activity. Loose stools, gut discomfort and pineapple/latex-related allergy are possible. |
Caution [FORM // CHECK_SPECIFICATION] GDU/FIP units are not convertible from mass without an activity assay. Joint and dental findings do not establish general digestion benefit. |
| Papain from papaya Best for: Identifying ingredient-specific precautions. |
Unstandardized: active content unknown | no comparable trial range | Proteolytic action; clinical evidence for broad OTC claims is weak. Can cause throat/esophageal irritation or papaya/latex-related allergy. |
Caution [FORM // CHECK_SPECIFICATION] No reliable activity-to-mg conversion is available. |
| Broad-spectrum enzyme blend with or without betaine HCl Best for: Reading separate activity units and all added ingredients. |
Unstandardized: active content unknown | no comparable trial range | Mixed activities and formulation-specific acid stability. Variable; betaine-containing products can cause burning. |
Caution [FORM // CHECK_SPECIFICATION] No common mg efficacy target; betaine HCl is not an enzyme. |
Common label traps
- TRAP_01 // PRESCRIPTION EVIDENCE PROVES MY OTC BLEND
PERT evidence concerns diagnosed EPI and activity-controlled, often enteric-coated medicines. - TRAP_02 // GLUTEN ENZYMES MAKE CELIAC GLUTEN EXPOSURE SAFE
Clinical protection is not established; do not use them to replace a gluten-free diet. - TRAP_03 // WORSE BLOATING IS DIE-OFF
No evidence in this dossier establishes a beneficial detox or die-off response to enzymes. Worsening symptoms warrant reassessment. - TRAP_04 // ENZYMES TREAT AUTISM
The cited double-blind RCT found no meaningful clinical benefit versus placebo.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- DIAGNOSED EPI: FAT ABSORPTION Strong · benefit
Meta-analysis and controlled trials show improved fat absorption and nutritional measures with prescription PERT in chronic pancreatitis or after pancreatic surgery.
PMID 27941156 PMID 20502447 PMID 8853261 PMID 26495784 - EPI IN OTHER CLINICAL SETTINGS Limited · benefit
Reviews address pancreatic cancer, upper-GI surgery and cystic fibrosis; evidence and timing remain heterogeneous and condition-specific.
PMID 32631175 PMID 38064682 PMID 34339047 PMID 39901161 - LACTOSE INTOLERANCE Limited · benefit
Small randomized evidence supports tilactase for lactose-related symptoms; benefit is tied to the lactose-containing meal.
PMID 20391953 - POST-MEAL FULLNESS Limited · benefit
A 16-person crossover RCT found less perceived fullness after a fatty meal with acid-resistant lipase; one-meal subjective response does not establish long-term benefit.
PMID 25287168 - BROMELAIN: JOINT / DENTAL SYMPTOMS Limited · benefit
Small, sometimes open-label or manufacturer-linked studies suggest symptom benefits. Several catalog records lack titles, preventing a publication-ready reference list; inflammatory-marker findings are inconsistent.
PMID 37202035 PMID 14631536 - FUNCTIONAL BOWEL SYMPTOMS Limited · benefit
Reviews discuss enzyme therapy, but observational EPI findings in some IBS-D patients indicate a diagnostic question, not proven benefit from broad OTC blends.
PMID 30101562 PMID 35704255 PMID 19835990 - CELIAC GLUTEN PROTECTION Limited · no benefit
The pilot does not establish protection sufficient to permit safe gluten consumption in celiac disease.
PMID 24124328 - AUTISM SPECTRUM DISORDER Limited · no benefit
The cited double-blind randomized trial did not establish clinically meaningful benefit over placebo.
PMID 20204691
Reader questions
How much should I take and when?
Use the relevant activity units and indication. Prescription PERT is individualized with meals; lactase is matched to lactose exposure. A capsule mg value alone cannot be judged by this calculator.
Could enzymes worsen my symptoms?
Yes: irritation, diarrhea or allergy can occur, and added betaine can cause burning. Increased symptoms are not proof of die-off; stop and reassess, with medical care for severe pain or allergic symptoms.
Can I self-treat oily stools or suspected EPI?
Persistent greasy stools or weight loss need clinical evaluation, potentially including pancreatic function testing. An OTC blend cannot substitute for a diagnosis or a supervised prescription.
Can a gluten enzyme let me eat gluten with celiac disease?
No reliable protective clinical strategy is established here. Continue the prescribed gluten-free approach; an enzyme is not a safeguard against intentional exposure.
Stack interactions
- Caution Anticoagulants / antiplatelets [CAUTION // REVIEW_COMBINATION]
Bromelain or papain have precautionary bleeding concerns based on mechanistic/case-level information. Review before surgery or combining; do not stop prescribed medicines yourself. - Caution Diabetes medicines / PERT [CAUTION // REVIEW_COMBINATION]
Changing digestion and absorption may change glycemic management in pancreatic disease. A clinical pancrelipase analysis included people with diabetes; this is not justification for unsupervised dosing.
PMID 26495784 - Caution Betaine HCl / curcumin combinations [CAUTION // REVIEW_COMBINATION]
Betaine can add burning and has a distinct acid mechanism. Marketed bromelain-curcumin synergy is not established by the supplied human evidence.
Red flags: interactions and who should avoid it
Interactions
Bromelain/papain may increase bleeding risk with anticoagulants or antiplatelets, but evidence is mechanistic/case-based rather than robust RCT evidence. Old small studies suggest bromelain may change some antibiotic concentrations; relevance is uncertain. PERT can change nutrient absorption and glycemic needs in pancreatic diabetes. Betaine HCl is an acid rather than an enzyme and can add burning.
Avoid or ask a doctor first if
Pineapple/papaya allergy and latex-fruit cross-reactions matter for bromelain/papain. Avoid unsupervised high-dose use in pregnancy/lactation and during acute pancreatic illness. Oily stools, weight loss or persistent malabsorption require diagnosis; children with cystic fibrosis need supervised PERT. Worsening bloating, pain or allergic symptoms are not evidence of detoxification.
Sources (PubMed, 17)
- Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis.
PMID 27941156 · 2017 · Systematic review / meta-analysisMeta-analysis of PERT for EPI in chronic pancreatitis: fat absorption and nutrition.
- Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
PMID 20502447 · 2010 · Randomized controlled trialRandomized delayed-release pancrelipase trial in chronic pancreatitis or pancreatic surgery.
- Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
PMID 8853261 · 1996 · Randomized controlled trialComparison of pancreatic-enzyme preparations in chronic-pancreatitis EPI.
- Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
PMID 26495784 · 2016 · Randomized controlled trialEfficacy and safety of pancrelipase/pancreatin in EPI with a diabetes history.
- Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis.
PMID 32631175 · 2020 · Systematic review / meta-analysisEPI and PERT in advanced pancreatic cancer; clinical population distinct from healthy supplement users.
- Pancreatic exocrine insufficiency after non-pancreatic upper gastrointestinal surgery: meta-analysis.
PMID 38064682 · 2024 · Systematic review / meta-analysisMeta-analysis of EPI after upper-GI surgery.
- Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis.
PMID 34339047 · 2021 · Systematic review / meta-analysisSystematic review of PERT timing in cystic fibrosis; timing evidence gap.
- Pancreatic exocrine insufficiency after pancreatic resection: a systematic review.
PMID 39901161 · 2025 · Systematic review / meta-analysisSystematic review of EPI after pancreatic resection.
- The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial.
PMID 20391953 · 2010 · Randomized controlled trialSmall tilactase trial in lactose intolerance.
- Lipase Supplementation before a High-Fat Meal Reduces Perceptions of Fullness in Healthy Subjects.
PMID 25287168 · 2015 · Randomized controlled trialAcute perceived fullness after a fatty meal; small healthy-subject trial.
- Bromelain supplementation and inflammatory markers: A systematic review of clinical trials.
PMID 37202035 · 2023 · Systematic review / meta-analysisSystematic review reports inconsistent inflammatory-marker results with bromelain.
- [Proteolytic enzymes as an alternative in comparison with nonsteroidal anti-inflammatory drugs (NSAID) in the treatment of degenerative and inflammatory rheumatic disease: systematic review].
PMID 14631536 · 2003 · Systematic review / meta-analysisProteolytic oral enzyme therapies versus NSAIDs in rheumatic disease; does not establish efficacy for an arbitrary OTC blend.
- Enzyme therapy for functional bowel disease-like post-prandial distress.
PMID 30101562 · 2018 · Narrative reviewReview of enzyme therapy for functional bowel-like post-meal distress.
- Exocrine Pancreatic Insufficiency is Undiagnosed in Some Patients with Diarrhea-Predominant Irritable Bowel Syndrome Using the Rome IV Criteria.
PMID 35704255 · 2022 · Observational studyObservational evidence of undiagnosed EPI in some IBS-D patients.
- Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency.
PMID 19835990 · 2010 · Cohort studySome IBS patients had pancreatic insufficiency; association is not an OTC treatment trial.
- Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study.
PMID 24124328 · 2013 · Randomized controlled trialGluten-degrading enzyme pilot does not establish clinically protective permission for gluten exposure in celiac disease.
- Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial.
PMID 20204691 · 2010 · Randomized controlled trialDouble-blind ASD trial: no meaningful benefit established.
Community comments
No approved comments yet. Comments are held for moderation.